NASDAQ:ABAX - Abaxis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$83.00 +83.00 (+∞)
(As of 08/1/2018)
Previous Close$83.00
Today's Range$83.00 - $83.00
52-Week Range$43.66 - $83.98
VolumeN/A
Average Volume167,754 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.

Receive ABAX News and Ratings via Email

Sign-up to receive the latest news and ratings for ABAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABAX
CUSIP00256710
Phone510-675-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Abaxis (NASDAQ:ABAX) Frequently Asked Questions

What is Abaxis' stock symbol?

Abaxis trades on the NASDAQ under the ticker symbol "ABAX."

How often does Abaxis pay dividends? What is the dividend yield for Abaxis?

Abaxis declared a quarterly dividend on Thursday, April 26th. Shareholders of record on Friday, June 1st will be given a dividend of $0.18 per share on Friday, June 15th. This represents a $0.72 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Thursday, May 31st. This is a positive change from Abaxis's previous quarterly dividend of $0.16. View Abaxis' Dividend History.

How will Abaxis' stock buyback program work?

Abaxis announced that its board has authorized a stock buyback program on Wednesday, October 25th 2017, which permits the company to buyback $21,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company's leadership believes its stock is undervalued.

How were Abaxis' earnings last quarter?

Abaxis Inc (NASDAQ:ABAX) posted its quarterly earnings data on Thursday, April, 26th. The medical research company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.10. The medical research company had revenue of $67.90 million for the quarter, compared to the consensus estimate of $66.02 million. The business's revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.33 EPS. View Abaxis' Earnings History.

What price target have analysts set for ABAX?

3 equities research analysts have issued 1-year price objectives for Abaxis' stock. Their predictions range from $62.00 to $62.00. On average, they expect Abaxis' stock price to reach $62.00 in the next twelve months. This suggests that the stock has a possible downside of 25.3%. View Analyst Price Targets for Abaxis.

What is the consensus analysts' recommendation for Abaxis?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abaxis in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Abaxis.

Has Abaxis been receiving favorable news coverage?

Media coverage about ABAX stock has trended neutral this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Abaxis earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.

Who are some of Abaxis' key competitors?

What other stocks do shareholders of Abaxis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abaxis investors own include Skyworks Solutions (SWKS), Akorn (AKRX), Gilead Sciences (GILD), Wells Fargo & Co (WFC), Amicus Therapeutics (FOLD), Abbott Laboratories (ABT), Celgene (CELG), Exelixis (EXEL), Incyte (INCY) and Mylan (MYL).

Who are Abaxis' key executives?

Abaxis' management team includes the folowing people:
  • Mr. Clinton H. Severson, Chairman & CEO (Age 70)
  • Mr. Donald P. Wood, Pres & COO (Age 66)
  • Mr. Ross Taylor Jr., CFO, VP of Fin. & Sec. (Age 55)
  • Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
  • Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)

How do I buy shares of Abaxis?

Shares of ABAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abaxis' stock price today?

One share of ABAX stock can currently be purchased for approximately $83.00.

What is Abaxis' official website?

The official website for Abaxis is http://www.abaxis.com.

How can I contact Abaxis?

Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]


MarketBeat Community Rating for Abaxis (NASDAQ ABAX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  324 (Vote Underperform)
Total Votes:  537
MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe ABAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel